Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Issues related to international taxation of corporations.
Duration: January 1, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code
Spending: about $1,160,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Related Foreign Entities:
Horizon Pharma PLC (Dublin, IRL); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Beau Schuyler
LD - Cong. Tanner, LD - Cong, McIntyre
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301574596.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301539758.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $50,000. The report was filed on Oct. 19, 2023.
Original Filing: 301509363.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301484720.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301463195.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436195.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.*
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301420063.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines.
Legislation supporting the Orphan Drug Act.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.*
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301393323.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301369333.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328557.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals.
Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313832.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Issues regarding line-extension for pharmaceuticals in a CMS rulemaking.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to international taxation of corporations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289316.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Issues regarding line-extension for pharmaceuticals in a CMS rulemaking.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301262381.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding pharmaceutical vial sizes. Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Issues regarding line-extension for pharmaceuticals in a CMS rulemaking.
Issues related to pharmaceutical shortages.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241406.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding pharmaceutical vial sizes.
H.R. 133, Consolidating Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation. Issues regarding line-extension for pharmaceuticals in a CMS rulemaking.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301220819.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. The Cares Act (P.L. 116-136), all provisions pertaining to corporate tax.
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation. Issues regarding line-extension for pharmaceuticals in a CMS rulemaking.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301196538.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Patient Protection and Affordable Care Enhancement Act (H.R. 1425). The Cares Act, PL 116-136, all provisions pertaining to corporate tax, and CMS home infusion benefits.
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301176226.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation. Issues regarding home infusion of medicines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, Thorn Run Partners lobbied for Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128813.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
Thorn Run Partners amended a lobbying report for representation of Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc) in Q32019 on Dec. 3, 2019.
Original Filing: 301091909.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, Thorn Run Partners lobbied for Horizon Pharma USA, Inc , earning $50,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066370.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to Medicare Part B and Part D. International Pricing Index proposals. Legislation regarding drug importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
In Q2, Thorn Run Partners lobbied for Horizon Pharma USA, Inc , earning $50,000. The report was filed on July 10, 2019.
Original Filing: 301044324.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, Thorn Run Partners lobbied for Horizon Pharma USA, Inc , earning $50,000. The report was filed on April 17, 2019.
Original Filing: 301027607.xml
Lobbying Issues
Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Legislation encouraging research for cystinosis.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
Thorn Run Partners filed a lobbying registration on Feb. 13, 2019 to represent Horizon Pharma USA, Inc, effective Jan. 1, 2019.
Original Filing: 301020285.xml
Issue(s) they said they’d lobby about: Issues related to orphan drugs and the value of innovative medicines. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate